SEARCH

SEARCH BY CITATION

References

  • Arunlakshana O, Schild HO (1959). Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14: 4858.
  • Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F et al. (2003). The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63: 908914.
  • Birdsall NJ, Lazareno S, Matsui H (1996). Allosteric regulation of muscarinic receptors. Prog Brain Res 109: 147151.
  • Bloxham J, Fyfe MCT, Horswill J, Jeevaratnam RP, Keily J, Procter MJ et al. (2006). Arylurea derivatives. International Patent Application Publication WO 2006/018662.
  • Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M et al. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interaction. J Biol Chem 272: 2233022339.
  • Campbell RM, Cartwright C, Chen W, Chen Y, Duzic E, Fu JM et al. (1999). Selective A1-adenosine receptor antagonists identified using yeast Saccharomyces cerevisiae functional assays. Bioorg Med Chem Lett 9: 24132418.
  • Casellas P, Congy C, Martinez S, Rinaldi M, Anne-Archard G (1997). Substituted N-piperidino 3-pyrazolecarboxamide. European patent EP 0656354.
  • Cheng YC, Prusoff WH (1973). Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22: 30993108.
  • Christopoulos A, Kenakin T (2002). G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323374.
  • Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998). Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 63: 113117.
  • Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 36: 605613.
  • Di Marzo V, Bifulco M, De Petrocellis L (2004). The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Dis 3: 771784.
  • Ellis J, Huyler J, Brann MR (1991). Allosteric regulation of cloned m1–m5 muscarinic receptor subtypes. Biochem Pharmacol 42: 19271932.
  • Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L et al. (2003). Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a ‘CB3’ receptor. Eur J Pharmacol 7: 2734.
  • Gao ZG, Kim SG, Soltysiak KA, Melman N, Ijzerman AP, Jacobson KA (2002). Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. Mol Pharmacol 62: 8189.
  • Gerard CM, Mollereau C, Vassart G, Parmentier M (1991). Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279: 129134.
  • Hilf G, Jakobs KH (1992). Activation of solubilized G-proteins by muscarinic acetylcholine receptors. Cell Signal 4: 787794.
  • Hoare SR, Coldwell MC, Armstrong D, Strange PG (2000). Regulation of human D(1), D(2(long)), D(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. Br J Pharmacol 130: 10451059.
  • Jensen AA, Spalding TA (2004). Allosteric modulation of g-protein coupled receptors. Eur J Pharm Sci 21: 407420.
  • Kew JN (2004). Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol Ther 104: 233244.
  • King K, Dohlman HG, Thorner J, Caron MG, Lefkowitz RJ (1990). Control of yeast mating signal transduction by a mammalian beta 2-adrenergic receptor and Gs alpha subunit. Science 250: 121123.
  • Matsuda LA, Bonner TI, Lolait SJ (1993). Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 22: 535550.
  • Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561564.
  • May LT, Christopoulos A (2003). Allosteric modulators of G-protein-coupled receptors. Curr Opin Pharmacol 3: 551556.
  • Miret JJ, Rakhilina L, Silverman L, Oehlen B (2002). Functional expression of heteromeric calcitonin gene-related peptide and adrenomedullin receptors in yeast. J Biol Chem 277: 68816887.
  • Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 6165.
  • Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006). Effect of Rimonabamt, a cannabinoid-1 receptor blocker, on weight and cardiometric risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA 295: 761775.
  • Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R et al. (2005). Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68: 14841495.
  • Soudijn W, Van Wijngaarden J, Ijzerman AP (2004). Allosteric modulation of G protein-coupled receptors: perspectives and recent developments. Drug Discov Today 9: 752758.
  • Urwyler S, Mosbacher J, Lingenhoehl K, Heid J, Hofstetter K, Froestl W et al. (2001). Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(b) receptors by 2, 6-di-tert-butyl-4-(3-hydroxy-2, 2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 60: 963971.
  • Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA (2003). Preferential effects of the cannabinoid CB1 receptor antagonist, SR141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology 167: 103111.
  • Zahn K, Ekstein N, Trankle C, Sadee W, Mohr K (2002). Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. J Pharmacol Exp Ther 301: 720728.